Dopamine transporter: Basic aspects and neuroimaging

Movement Disorders

Volumn 18, Issue SUPPL. 7, 2003, Pages

  Piccini, Paola P ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Dopamine transporter; Neuroimaging; PET; Radiotracers; SPECT

Indexed keywords

3BETA (4 FLUOROPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; 3BETA (4 IODOPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; ALTROPANE; AMPHETAMINE; APOMORPHINE; BROMOCRIPTINE; CARBIDOPA; CARBON 11; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; DOPAMINE TRANSPORTER; FLUORINE 18; IODINE 123; LEVODOPA; METHYLPHENIDATE; NEUROTRANSMITTER; NOMIFENSINE; NORTROPANE DERIVATIVE; PERGOLIDE; PRAMIPEXOLE; PSYCHOSTIMULANT AGENT; PSYCHOTROPIC AGENT; QUINPIROLE; RADIOISOTOPE; ROPINIROLE; SELEGILINE; TECHNETIUM 99M; TRACER; UNINDEXED DRUG;

AGE; ARTICLE; DIAGNOSTIC VALUE; DOPAMINERGIC NERVE CELL; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SELECTIVITY; FEMALE; GENDER; HUMAN; IN VIVO STUDY; MALE; NERVE CELL MEMBRANE; NEUROTRANSMITTER RELEASE; NIGRONEOSTRIATAL SYSTEM; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRESYNAPTIC NERVE; PRIORITY JOURNAL; RISK FACTOR; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SMOKING HABIT; TISSUE DISTRIBUTION;

ANIMALS; BRAIN; CARBON RADIOISOTOPES; CORPUS STRIATUM; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINE UPTAKE INHIBITORS; HUMANS; IODINE RADIOISOTOPES; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; NERVE DEGENERATION; NERVE TISSUE PROTEINS; NEURAL PATHWAYS; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA; TECHNETIUM; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0242382831     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.10571     Document Type: Article

References (63)

1. Amara SG. Neurotransmitter transporters. A tale of two families. Nature 1992;360:420-421.
2. Amara SG, Arriza JL. Neurotransmitter transporters: three distinct gene families. Curr Opin Neurobiol 1993;3:337-344.
3. Kanner BI, Schuldiner S. Mechanism of transport and storage of neurotransmitters. CRC Crit Rev Biochem 1987;22:1-38.
4. Kavanaugh MP, Arriza JL, North RA, Amara SG. Electrogenic uptake of gamma-aminobutyric acid by a cloned transporter expressed in Xenopus oocytes. J Biol Chem 1992;267:22007-22009.
5. Zerangue N, Kavanaugh MP. Flux coupling in a neuronal glutamate transporter. Nature 1996;383:634-637.
6. Liu Y, Edwards RH. The role of vesicular transport proteins in synaptic transmission and neural degeneration. Annu Rev Neurosci 1997;20:125-156.
7. McIntire SL, Reimer RJ, Schuske K, Edwards RH, Jorgensen EM. Identification and characterization of the vesicular GABA transporter. Nature 1997;389:870-876.
8. Giros B, el Mestikawy S, Bertrand L, Caron MG. Cloning and functional characterization of a cocaine-sensitive dopamine transporter. FEBS Lett 1991;295:149-154.
9. Kilty JE, Lorang D, Amara SG. Cloning and expression of a cocaine-sensitive rat dopamine transporter. Science 1991;254:578-579.
10. Shimada S, Kitayama S, Lin CL, et al. Cloning and expression of a cocaine-sensitive dopamine transporter complementary DNA. Science 1991;254:576-578.
11. Giros B, Caron MG. Molecular characterization of the dopamine transporter. Trends Pharmacol Sci 1993;14:43-49.
12. - neurotransmitter transporters. J Neurochem 1998;71:1785-1803.
13. Worrall DM, Williams DC. Sodium ion-dependent transporters for neurotransmitters: a review of recent developments. Biochem J 1994;297:425-436.
14. Pristupa ZB, McConkey F, Liu F, Man HY, Lee FJ, Wang YT, Niznik HB. Protein kinase-mediated bidirectional trafficking and functional regulation of the human dopamine transporter. Synapse 1998;30:79-87.
15. Masson J, Sagne C, Hamon M, El Mestikawy S. Neurotransmitter transporters in the central nervous system. Pharmacol Rev 1999; 51:439-464.
16. Ciliax BJ, Heilman C, Demchyshyn LL, et al. The dopamine transporter: immunochemical characterization and localization in brain. J Neurosci 1995;15:1714-1723.
17. Freed C, Revay R, Vaughan RA, Kriek E, Grant S, Uhl GR, Kuhar MJ. Dopamine transporter immunoreactivity in rat brain. J Comp Neurol 1995;359:340-349.
18. Nirenberg MJ, Vaughan RA, Uhl GR, Kuhar MJ, Pickel VM. The dopamine transporter is localized to dendritic and axonal plasma membranes of nigrostriatal dopaminergic neurons. J Neurosci 1996;16:436-447.
19. Hersch SM, Yi H, Heilman CJ, Edwards RH, Levey AI. Subcellular localization and molecular topology of the dopamine transporter in the striatum and substantia nigra. J Comp Neurol 1997;388:211-227.
20. Liu Y, Krantz DE, Waites C, Edwards RH. Membrane trafficking of neurotransmitter transporters in the regulation of synaptic transmission. Trends Cell Biol 1999;9:356-363.
21. Donnan GA, Kaczmarczyk SJ, Paxinos G, Chilco PJ, Kalnins RM, Woodhouse DG, Mendelsohn FA. Distribution of catecholamine uptake sites in human brain as determined by quantitative [3H] mazindol autoradiography. J Comp Neurol 1991;304:419-434.
22. Hoffman BJ Molecular biology of dopamine transporters. In: Niznik HB, editor. New York: Marcel Dekker; 1994. p 645-668.
23. Amara SG, Kuhar MJ. Neurotransmitter transporters: recent progress. Annu Rev Neurosci 1993;16:73-93.
24. Koob GF, Bloom FE. Cellular and molecular mechanisms of drug dependence. Science 1988;242:715-723.
25. Self DW, Nestler EJ. Molecular mechanisms of drug reinforcement and addiction. Annu Rev Neurosci 1995;18:463-495.
26. Wise RA. Addictive drugs and brain stimulation reward. Annu Rev Neurosci 1996;19:319-340.
27. Seiden LS, Sabol KE, Ricaurte GA. Amphetamine: effects on catecholamine systems and behavior. Annu Rev Pharmacol Toxicol 1993;33:639-677.
28. Sulzer D, Chen TK, Lau YY, Kristensen H, Rayport S, Ewing A. Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. J Neurosci 1995;15:4102-4108.
29. Jones SR, Gainetdinov RR, Wightman RM, Caron MG. Mechanisms of amphetamine action revealed in mice lacking the dopamine transporter. J Neurosci 1998;18:1979-1986.
30. Giros B, Wang YM, Suter S, McLeskey SB, Pifl C, Caron MG. Delineation of discrete domains for substrate, cocaine, and tricyclic antidepressant interactions using chimeric dopamine-norepinephrine transporters. J Biol Chem 1994;269:15985-15988.
31. Leenders KL, Aquilonius SM, Bergstrom K, et al. Unilateral MPTP lesion in a rhesus monkey: effects on the striatal dopaminergic system measured in vivo with PET using various novel tracers. Brain Res 1988;445:61-67.
32. Leenders KL, Salmon EP, Tyrrell P, et al. The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease. Arch Neurol 1990;47:1290-1298.
33. 3H]2 β-carbomethoxy-3 β(4-fluorophenyl)tropane. Mol Pharmacol 1989;36:518-524.
34. 3H]WIN 35,428) in the monkey brain. Synapse 1990;6:189-195.
35. 123I]-2 β-carbomethoxy-3 β(4-iodophenyl)tropane: high-affinity SPECT radiotracer of mono-amine reuptake sites in brain. J Med Chem 1991;34:3144-3146.
36. Kaufman MJ, Madras BK. Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson's-diseased striatum. Synapse 1991;9:43-49.
37. 11C]WIN 35,428. Synapse 1993;15:130-142.
38. 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease. Ann Neurol 1993;34:423-431.
39. 125I]RTI-55: a potent ligand for dopamine transporters. Eur J Pharmacol 1991;194:133-134.
40. 123I]CIT. Eur J Pharmacol 1991;200:369-370.
41. 123I]β-CIT: pharmacological characterization of brain uptake in nonhuman primates. Synapse 1993;13:295-309.
42. 123I]β-CIT binding to dopamine transporters in healthy human subjects. J Cereb Blood Flow Metab 1994;14:982-994.
43. Abi-Dargham A, Gandelman MS, DeErausquin GA, et al. SPECT imaging of dopamine transporters in human brain with iodine-123-fluoroalkyl analogs of β-CIT. J Nucl Med 1996;37:1129-1133.
44. 123I]FP-CIT: a potent radioligand for imaging of dopamine transporters. Eur J Nucl Med 1998;25:24-30.
45. Ishikawa T, Dhawan V, Kazumata K, et al. Comparative nigrostriatal dopaminergic imaging with iodine-123-beta CIT-FP/SPECT and fluorine-18-FDOPA/PET. J Nucl Med 1996;37:1760-1765.
46. Emond P, Garreau L, Chalon S, et al. Synthesis and ligand binding of nortropane derivatives: N-substituted 2β-carbomethoxy-3β-(4′-iodophenyl) nortropane and N-(3-iodoprop-(2E)-enyl -2β-carbo-methoxy-3β-(3′,4′-disubstituted phenyl nortropane. New high-affinity and selective compounds for the dopamine transporter. J Med Chem 1997;40:1366-1372.
47. Chalon S, Emond P, Bodard S, Vilar MP, Thiercelin C, Besnard JC, Guilloteau D. Time course of changes in striatal dopamine transporters and D2 receptors with specific iodinated markers in a rat model of Parkinson's disease. Synapse 1999;31:134-139.
48. Volkow ND, Fowler JS, Wang GJ, et al. Decreased dopamine transporters with age in health human subjects. Ann Neurol 1994; 36:23723-23729.
49. Zelnik N, Angel I, Paul SM, Kleinman JE. Decreased density of human striatal dopamine uptake sites with age. Eur J Pharmacol 1986;126:175-176.
50. De Keyser J, Ebinger G, Vauquelin G. Age-related changes in the human nigrostriatal dopaminergic system. Ann Neurol 1990;27: 157-161.
51. van Dyck CH, Seibyl JP, Malison RT, et al. Age-related decline in striatal dopamine transporter binding with iodine-123-beta-CIT SPECT. J Nucl Med 1995;36:1175-1181.
52. Fischman AJ, Bonab AA, Babicb JW, et al. Rapid detection of Parkinson's disease by SPECT with altropane: a selective ligand for dopamine transporters. Synapse 1998;29:128-141.
53. 123I]FP-CIT SPET in healthy volunteers. Eur J Nucl Med 2000; 27:867-869.
54. Crooks PA, Dwoskin LP. Contribution of CNS nicotine metabolites to the neuropharmacological effects of nicotine and tobacco smoking. Biochem Pharmacol 1997;54:743-753.
55. 123I]β-CIT SPECT measures of dopamine and serotonin transporter availability in healthy smokers and nonsmokers. Synapse 2001;41:275-284.
56. 99mTc]TRODAT-1 to the central dopamine transporters in rats. Eur J Nucl Med 1998;25:31-39.
57. 3H]cocaine in mice. Neurosci Lett 1996;205:145-148.
58. Gordon I, Weizman R, Rehavi M. Modulatory effect of agents active in the presynaptic dopaminergic system on the striatal dopamine transporter. Eur J Pharmacol 1996;298:27-30.
59. Moody CA, Granneman JG, Bannon MJ. Dopamine transporter binding in rat striatum and nucleus accumbens is unaltered following chronic changes in dopamine levels. Neurosci Lett 1996;217:55-57.
60. Gnanalingham KK, Robertson RG. The effects of chronic continuous versus intermittent levodopa treatments on striatal and extrastriatal D1 and D2 dopamine receptors and dopamine uptake sites in the 6-hydroxydopamine lesioned rat - an autoradiographic study. Brain Res 1994;640:185-194.
61. Little KY, Gorebig J, Carroll FI, Mapili J, Meador-Woodruff JH. Lack of dopamine receptor agonists effect on striatal dopamine transporter binding sites. Brain Res 1996;742:313-316.
62. 123I]β- CIT. Mov Disord 1999;14:436-442.
63. Ahlskog JE, Uitti RJ, O'Connor MK, et al. The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease. Mov Disord 1999;14:940-946.